WordNet

any of a series of volatile hydroxyl compounds that are made from hydrocarbons by distillation
a liquor or brew containing alcohol as the active agent; "alcohol (or drink) ruined him" (同)alcoholic drink, alcoholic_beverage, intoxicant, inebriant
the state of relying on or being controlled by someone or something else (同)dependance, dependency
tending to deter; "the deterrent effects of high prices"

PrepTutorEJDIC

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 有害なアルコールおよびその他の薬物使用への短期介入 brief intervention for unhealthy alcohol and other drug use
2. 物質使用障害の適切な治療レベルの決定 determining appropriate levels of care for treatment of substance use disorders
3. アルコール使用障害に対する薬物療法 pharmacotherapy for alcohol use disorder
4. アルコール使用障害：疫学、病因、臨床症状、有害事象、および診断 risky drinking and alcohol use disorder epidemiology pathogenesis clinical manifestations course assessment and diagnosis
5. アルコール使用障害の心理社会的治療 psychosocial treatment of alcohol use disorder

Methods and predictors of tampering with a tamper-resistant controlled-release oxycodone formulation.

Peacock A1, Degenhardt L2, Hordern A2, Larance B2, Cama E2, White N3, Kihas I2, Bruno R4.
The International journal on drug policy.Int J Drug Policy.2015 Dec;26(12):1265-72. doi: 10.1016/j.drugpo.2015.05.023. Epub 2015 Jun 7.
BACKGROUND: In April 2014, a tamper-resistant controlled-release oxycodone formulation was introduced into the Australian market. This study aimed to identify the level and methods of tampering with reformulated oxycodone, demographic and clinical characteristics of those who reported tampering with
PMID 26123898

The characteristics of a cohort who tamper with prescribed and diverted opioid medications.

Larance B1, Lintzeris N2, Bruno R3, Peacock A3, Cama E4, Ali R5, Kihas I4, Hordern A4, White N5, Degenhardt L6.
Journal of substance abuse treatment.J Subst Abuse Treat.2015 Nov;58:51-61. doi: 10.1016/j.jsat.2015.06.001. Epub 2015 Jun 24.
AIMS: To describe the methods and baseline characteristics of a cohort of people who tamper with pharmaceutical opioids, formed to examine changes in opioid use following introduction of Reformulated OxyContin®.METHODS: Participants were 606 people from three Australian jurisdictions who reported p
PMID 26286818

The introduction of a potentially abuse deterrent oxycodone formulation: Early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study.

Degenhardt L1, Bruno R2, Ali R3, Lintzeris N4, Farrell M5, Larance B5.
Drug and alcohol dependence.Drug Alcohol Depend.2015 Jun 1;151:56-67. doi: 10.1016/j.drugalcdep.2015.02.038. Epub 2015 Mar 16.
BACKGROUND: There is increasing concern about tampering of pharmaceutical opioids. We describe early findings from an Australian study examining the potential impact of the April 2014 introduction of an abuse-deterrent sustained-release oxycodone formulation (Reformulated OxyContin(®)).METHODS: Dat
PMID 25910850